Personal profile
Specialisation
Medical Oncology | Melanoma | Urological tumours | Immunotherapy
Research interests
- Evaluating Immunotherapy in Melanoma: studying biomarkers to predict toxicity and efficacy of immune checkpoint inhibitors in patients with early stage and advanced melanoma.
- Exploring local regional immunotherapy for melanoma: investigating local regional immuno-stimulating agents (e.g. TLR-receptor agonists, checkpoint inhibitors or cytokines) in early stage melanoma or integrating them in the treatment of advanced melanoma
- Innovative Clinical Trials: aiming to improve clinical outcomes for patients with melanoma and urological cancers, particularly focusing on the integration of new immunotherapeutic approaches.
- Monitoring quality of care for patients with melanoma or prostate cancer: investigating real world data to determine the efficacy and safety of new treatments for subgroups of patients with melanoma or prostate cancer.
Fons van den Eertwegh is Professor Clinical Immuno-Oncology at the Amsterdam UMC. He is medical oncologist and Immunologist specialized in the treatment of melanoma and urological tumours. He is recognised for his significant contributions to the field, particularly in the context of melanoma, prostate cancer and immunotherapy.
Activities
- Professor clinical immuno-oncology at the Amsterdam UMC.
- Member of Dutch Melanoma Skin Cancer Group (DMSCG)
- Chair if the Dutch Melanoma treatment registry (DMTR)
- Member of Dutch Society of Medical Oncology (NVMO)
- Member of European Society of Medical Oncology (ESMO)
- Member of American Society of Oncology (ASCO)
- Member of Dutch Society of Immunology (NVVI)
- Member of Dutch Society of Internal Medicine (NIV)
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics where Fons van den Eertwegh is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Adjuvant BRAF/MEK versus anti-PD-1 in BRAF-mutant melanoma: a propensity score matched survival analysis
Bloem, M., de Meza, M. M., van den Eertwegh, A. J. M., Aarts, M. J. B., van den Berkmortel, F. W. P. J., Blank, C. U., Blokx, W. A. M., Boers-Sonderen, M. J., Bonenkamp, J. J., Boreel, C. D. M., de Groot, J. W. B., Haanen, J. B. A. G., Hospers, G. A. P., Kapiteijn, E., van Not, O. J., Piersma, D., Rikhof, B., Stevense-den Boer, A. M., van der Veldt, A. A. M. & Vreugdenhil, G. & 2 others, , 29 Jun 2025, In: British journal of cancer. 132, 12, p. 1124-1130 7 p., 102290.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile23 Downloads (Pure) -
Artificial Intelligence-Detected Tumor-Infiltrating Lymphocytes and Outcomes in Anti-PD-1-Based Treated Melanoma
Schuiveling, M., van Duin, I. A. J., ter Maat, L. S., van der Weerd, J. C., Verheijden, R. J., van den Berkmortel, F., Blank, C. U., Breimer, G. E., Burgers, F. H., Boers-Sonderen, M., van den Eertwegh, A. J. M., de Groot, J. W. B., Haanen, J. B. A. G., Hospers, G. A. P., Kapiteijn, E., Piersma, D., Vreugdenhil, G., Westgeest, H., Schrader, A. M. R. & Pluim, J. P. W. & 4 others, , 18 Dec 2025, In: JAMA oncology. 11, 12, p. 1470-1478 9 p.Research output: Contribution to journal › Article › Academic › peer-review
Open Access -
Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial
Choueiri, T. K., Penkov, K., Uemura, H., Campbell, M. T., Pal, S., Kollmannsberger, C., Lee, J. L., Venugopal, B., van den Eertwegh, A. J. M., Negrier, S., Gurney, H., Albiges, L., Berger, R., Haanen, J. B. A. G., Oyervides Juárez, V., Rini, B. I., Larkin, J., Nolè, F., Schmidinger, M. & Atkins, M. B. & 7 others, , Apr 2025, In: Annals of oncology. 36, 4, p. 387-392 6 p.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile45 Downloads (Pure) -
Corrigendum to “Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry” [Eur. J. Cancer 212, 2024, 115056] (European Journal of Cancer (2024) 212, (S0959804924010220), (10.1016/j.ejca.2024.115056))
Özkan, A., Kapiteijn, E., van den Bos, F., Aarts, M. J. B., van den Berkmortel, F. W. P. J., Blank, C. U., Bloem, M., Blokx, W. A. M., Boers-Sonderen, M. J., Bonenkamp, J. J., van den Eertwegh, A. J. M., de Groot, J. W. B., Haanen, J. B., Holtslag, C. E., Hospers, G. A. P., Piersma, D., van Rijn, R. S., Stevense-den Boer, A. M., Suijkerbuijk, K. P. M. & van der Veldt, A. A. M. & 4 others, , 5 Feb 2025, In: European Journal of Cancer. 216, 115194.Research output: Contribution to journal › Comment/Letter to the editor › Academic
Open AccessFile22 Downloads (Pure) -
Cost-effectiveness of treatment sequences for BRAF-mutant advanced melanoma in the Netherlands using a health economic model
Blommestein, H. M., de Groot, S., Leeneman, B., Uyl-de Groot, C. A., Haanen, J. B. A. G., Wouters, M. W. J. M., Aarts, M. J. B., van den Berkmortel, F. W. P. J., Blokx, W. A. M., Boers-Sonderen, M. J., van den Eertwegh, A. J. M., de Groot, J. W. B., Hospers, G. A. P., Kapiteijn, E., van Not, O. J., van der Veldt, A. A. M., Suijkerbuijk, K. P. M. & Franken, M. G., 11 Mar 2025, In: European Journal of Cancer. 218, 115071.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile23 Downloads (Pure)